Evidence map›Paper›PMID 30875030›Full record

ArticlePathology oncology research : POR2020

Immunohistochemical Staining in the Assessment of Melanoma Tumor Thickness.

Kambiz Kamyab-Hesary, Alireza Ghanadan, Kamran Balighi, Seyede Faeze Mousavinia, Maryam Nasimi

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kambiz Kamyab-HesaryDepartment of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Alireza GhanadanDepartment of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Kamran BalighiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Vahdate Eslami Street, Tehran, 1199663911, Iran.
Seyede Faeze MousaviniaTehran University of Medical Sciences, Tehran, Iran.
Maryam NasimiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Vahdate Eslami Street, Tehran, 1199663911, Iran. Nsm.maryam@gmail.com.
Razi Hospital · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vertical tumor thickness has great influence in the prognosis and staging of melanoma. The aim of this study was determination of the differences between melanoma tumor thickness in conventional hematoxylin and eosin (H&E) and immunohistochemical techniques. Thirty-six biopsy specimens were included in our study. For each sample, four adjacent tissue sections were stained with H&E, in addition S-100, Melan- A and HMB-45 staining was performed on the next serial sections. The mean thickness of tumor invasion was 2.16, 2.38, 2.22 and 2.29 mm in H&E, S-100, HMB45 and Melan-A sections evaluation, respectively. The mean difference of the Breslow thickness between H&E and S-100 and also, between H&E and Melan-A stained slides were statistically significant (p˂0.05) while no difference was found in the tumor thickness of the H&E and HMB45 staining evaluation (p = 0.278). Greater tumor thickness was observed in 25 lesions (69.4%) with S-100, 20 lesions (55.5%) with Melan-A and 17 (47.2%) lesions in HMB-45 rather than H&E staining. Conclusively, it appears that H&E staining cannot prove the actual size of melanoma invasion in some cases and immunohistochemical examination can be a complementary method in this situations. Of the melanoma associated immunomarkers, the combination of S-100 and Melan-A staining may suffice to measure depth of tumor invasion.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCutaneous Malignant MelanomaFemaleHumansImmunohistochemistryMaleMelanomaMiddle AgedNeoplasm StagingSkin NeoplasmsStaining and LabelingBiomarkers, TumorBreslow thicknessImmunohistochemical stainingMelanoma

Identifiers

PMID30875030
OpenAlexW2921027173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.